Sensei Biotherapeutics Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 28

Employees

  • Stock Symbol
  • SNSE

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.05
  • (As of Friday Closing)

Sensei Biotherapeutics General Information

Description

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Contact Information

Formerly Known As
Panacea Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 1405 Research Boulevard
  • Suite 125
  • Rockville, MD 20850
  • United States
+1 (240) 000-0000

Sensei Biotherapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sensei Biotherapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.05 $1.09 $0.51 - $1.93 $26.3M 25.1M 70K -$1.22

Sensei Biotherapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV (47,944) (47,944) (62,387) 20,800
Revenue 0 0 0 0
EBITDA (36,981) (36,981) (49,552) (36,239)
Net Income (34,101) (34,101) (48,588) (36,794)
Total Assets 74,374 74,374 118,375 153,225
Total Debt 6,208 6,208 8,033 2,354
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sensei Biotherapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sensei Biotherapeutics‘s full profile, request access.

Request a free trial

Sensei Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Sensei Biotherapeutics‘s full profile, request access.

Request a free trial

Sensei Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation the
Drug Discovery
Rockville, MD
28 As of 2023
00000
00000 0000-00-00
00000000 00000

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labor
0000000000000
Andover, MA
00 As of 0000
00000
000000000000 00000

000000

co laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000000000000
Woburn, MA
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sensei Biotherapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oncorus Formerly VC-backed Andover, MA 00 00000 000000000000 00000
Replimune Formerly VC-backed Woburn, MA 000 00000 00000000 00000
Gritstone bio Formerly VC-backed Emeryville, CA 000 00000 00000000 00000
BioNTech Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
Vyriad Venture Capital-Backed Rochester, MN 00 00000 00000000000 00000
To view Sensei Biotherapeutics’s complete competitors history, request access »

Sensei Biotherapeutics Patents

Sensei Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230272082-A1 Anti-vista antibodies and uses thereof Pending 09-Nov-2021 00000000000
US-20200345820-A1 Combination therapies for cancer Inactive 01-May-2019 000000000
EP-3866841-A1 Compositions and methods for manufacturing bacteriophage cancer vaccines and uses thereof Inactive 19-Oct-2018 0000000000000
US-20200121773-A1 Compositions and methods for manufacturing bacteriophage cancer vaccines and uses thereof Inactive 19-Oct-2018 0000000000000
US-20190345261-A1 Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof Inactive 10-May-2018 C07K16/40
To view Sensei Biotherapeutics’s complete patent history, request access »

Sensei Biotherapeutics Executive Team (17)

Name Title Board Seat Contact Info
John Celebi President, Chief Executive Officer and Board Member
Edward Van der Horst Chief Scientific Officer
Stephanie Krebs Chief Business Officer
Patrick Gallagher Executive
Hossein Ghanbari Ph.D Founder, Chairman of the Board, and Chief Science Officer
You’re viewing 5 of 17 executive team members. Get the full list »

Sensei Biotherapeutics Board Members (16)

Name Representing Role Since
Alain Algazi MD Self Immuno-Oncology Advisory Board Member 000 0000
Deneen Vojta MD Self Board Member 000 0000
James Peyer Ph.D Cambrian Bio Board Member 000 0000
Jessie English Ph.D Self Board Member 000 0000
John Celebi Sensei Biotherapeutics President, Chief Executive Officer and Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Sensei Biotherapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sensei Biotherapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sensei Biotherapeutics‘s full profile, request access.

Request a free trial

Sensei Biotherapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alvaxa Biosciences 19-May-2020 0000000000 Biotechnology 0000 0000
To view Sensei Biotherapeutics’s complete acquisitions history, request access »

Sensei Biotherapeutics ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

36.08 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

0.000

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 965

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 443

Rank

00.00

Percentile

To view Sensei Biotherapeutics’s complete esg history, request access »

Sensei Biotherapeutics FAQs

  • When was Sensei Biotherapeutics founded?

    Sensei Biotherapeutics was founded in 1999.

  • Who is the founder of Sensei Biotherapeutics?

    Kasra Ghanbari and Hossein Ghanbari Ph.D are the founders of Sensei Biotherapeutics.

  • Who is the CEO of Sensei Biotherapeutics?

    John Celebi is the CEO of Sensei Biotherapeutics.

  • Where is Sensei Biotherapeutics headquartered?

    Sensei Biotherapeutics is headquartered in Rockville, MD.

  • What is the size of Sensei Biotherapeutics?

    Sensei Biotherapeutics has 28 total employees.

  • What industry is Sensei Biotherapeutics in?

    Sensei Biotherapeutics’s primary industry is Drug Discovery.

  • Is Sensei Biotherapeutics a private or public company?

    Sensei Biotherapeutics is a Public company.

  • What is Sensei Biotherapeutics’s stock symbol?

    The ticker symbol for Sensei Biotherapeutics is SNSE.

  • What is the current stock price of Sensei Biotherapeutics?

    As of 12-Apr-2024 the stock price of Sensei Biotherapeutics is $1.05.

  • What is the current market cap of Sensei Biotherapeutics?

    The current market capitalization of Sensei Biotherapeutics is $26.3M.

  • Who are Sensei Biotherapeutics’s competitors?

    Oncorus, Replimune, Gritstone bio, BioNTech, and Vyriad are some of the 6 competitors of Sensei Biotherapeutics.

  • What is Sensei Biotherapeutics’s annual earnings per share (EPS)?

    Sensei Biotherapeutics’s EPS for 12 months was -$1.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »